Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$844 Mln
Revenue (TTM)
$240 Mln
Net Profit (TTM)
$-38 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.4
Industry P/E
54.26
EV/EBITDA
-14.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1
Face value
--
Shares outstanding
42,198,000
CFO
$-81.99 Mln
EBITDA
$-184.81 Mln
Net Profit
$-225.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cardiovascular Systems (CSII)
| 46.8 | 0.7 | 42.1 | 7.0 | -20.8 | -3.0 | 1.5 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Cardiovascular Systems (CSII)
| -27.5 | -57.1 | -9.9 | 70.6 | 20.1 | -2.1 | 60.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products... comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota. As of April 27, 2023, Cardiovascular Systems, Inc. operates as subsidiary of Abbott Laboratories (NYSE:ABT). Read more
Chairman, Pres & CEO
Mr. Scott Raymond Ward B.Sc., M.S., MS
Chairman, Pres & CEO
Mr. Scott Raymond Ward B.Sc., M.S., MS
Headquarters
Saint Paul, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cardiovascular Systems Inc (CSII) is $20.00 (NASDAQ) as of 02-May-2023 09:30 EDT. Cardiovascular Systems Inc (CSII) has given a return of -20.83% in the last 3 years.
Since, TTM earnings of Cardiovascular Systems Inc (CSII) is negative, P/E ratio is not available.
The P/B ratio of Cardiovascular Systems Inc (CSII) is 2.43 times as on 02-May-2023, a 18 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-15.16
|
2.24
|
|
2021
|
-123.94
|
6.14
|
|
2020
|
-39.39
|
3.99
|
|
2019
|
-5,724.00
|
9.87
|
|
2018
|
642.27
|
8.18
|
The 52-week high and low of Cardiovascular Systems Inc (CSII) are Rs -- and Rs -- as of 03-Apr-2026.
Cardiovascular Systems Inc (CSII) has a market capitalisation of $ 844 Mln as on 02-May-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Cardiovascular Systems Inc (CSII), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.